Barreiro Pablo, Camino Nuria, De Julián Rosa, González-Lahoz Juan, Soriano Vincent
Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain.
HIV Clin Trials. 2003 Jul-Aug;4(4):244-7. doi: 10.1310/g67j-c2nc-2xrd-ttmm.
The outcome of 162 patients replacing protease inhibitors (PIs) by nonnucleoside reverse transcriptase inhibitors (NNRTIs) was retrospectively assessed. After 48 weeks of follow-up, nevirapine (NVP) and efavirenz (EFV) performed similarly well in simplification interventions in patients with undetectable viremia, while EFV provided significantly better results in rescue interventions after PI failure. Previous suboptimal exposure to nucleoside analogs conditioned lower chances of virologic success using either NVP or EFV. Both drugs were generally well tolerated, although specific toxicities could make one drug more suitable than the other for certain patients.
对162例用非核苷类逆转录酶抑制剂（NNRTIs）替代蛋白酶抑制剂（PIs）的患者的治疗结果进行了回顾性评估。经过48周的随访，奈韦拉平（NVP）和依非韦伦（EFV）在病毒血症检测不到的患者的简化治疗干预中表现相似，而EFV在PI治疗失败后的挽救治疗干预中效果显著更好。先前核苷类似物暴露不足使使用NVP或EFV获得病毒学成功的机会降低。两种药物总体耐受性良好，尽管特定毒性可能使一种药物对某些患者比另一种更合适。
